검색어: cytopenia (영어 - 몰타어)

refractory cytopenia
Ċitopenija refrattorja

thrombo- cytopenia
tromboċito penja

if cytopenia persists for
jekk iċ-ċitopenja tippersisti għal ġimagħtejn,erġa’ naqqas għal 300 mg.

anaemia, thrombo- cytopenia
anemija, thromboċitopenij a

if recurrence of cytopenia, repeat step 1
f' każ ta 'rikorrenza ta' ċitopenja,

neutropenia, leukopenia, anaemia, thrombo- cytopenia
newtropenja, lewkopenija, anemija, trombo- citopenija

febrile neutropenia, leucopenia, neutropeniaa, thrombo- cytopenia
newtropenija bid-deni, lewkopenija, newtropenijaa,

jakavi dose can be titrated to reduce the risk of cytopenia.
wieħed jista’ jagħmel titrazzjoni tad-doża ta’ jakavi sabiex jitnaqqas ir-riskju ta’ ċitopenija.

if cytopenia is unrelated to leukaemia, reduce dose of glivec to 400 mg.
jekk iċ-ċitopenja ma tkunx relatata mal- lewkimja, naqqas id-doża ta’ glivec għal 400 mg.

interruption of treatment should be considered in patients who develop unexplained cytopenia.
twaqqif tal-kura għandu jiġi kkunsidrat f’pazjenti li jiżviluppaw ċitopenija mingħajr raġuni.

if cytopenia is related to leukaemia, consider dose escalation to 100 mg twice daily.
jekk iċ- ċitopenja tkun relatata ma 'lewkimja, ikkunsidra żieda fid- doża sa 100 mg darbtejn kuljum.

check whether cytopenia is related to leukaemia (marrow aspirate or biopsy).
ara jekk iċ-ċitopenja hiex relatata mal- lewkimja (permezz ta’ aspirat mill- mudullun jew bijospija).

this includes an increased risk of skeletal manifestations, exacerbation of cytopenia, haemorrhage, and an increased need for transfusion.
dan jinkludi riskju ogħla ta’ manifestazzjonijiet skeletriċi, tħarrix ta’ ċitopenija, emorraġija u ħtieġa akbar ta’ trasfużjoni.

therefore all patients experienced profound cytopenia: leucopenia 96%, thrombocytopenia 94%, and anemia 88%.
għalhekk il-pazjenti kollha esperjenzaw ċitopenija profonda: lewkopenja 96%, tromboċitopenja 94%, u anemja 88%.

a cbc is recommended prior to initiating gilenya to ensure that immune effects of the previous therapy (i.e. cytopenia) have resolved.
huwa rrakkomandat li jsir cbc qabel ma jinbeda gilenya biex ikun assigurat li l-effetti immuni mit-terapija ta’ qabel (i.e. ċitopenija) jkunu ġew solvuti.

if the patient develops new or worsening morphological abnormalities or cytopenia(s), discontinue treatment with revolade and consider a bone marrow biopsy, including staining for fibrosis.
jekk il-pazjent jiżviluppa morfoloġiji mhux normali ġodda jew li jmorru għal agħar jew ċitopenija(i), waqqaf il-kura b’revolade u kkunsidra bijopsija tal-mudullun tal-għadam, li tinkludi staining għal fibrożi.

in paediatric cml patients the most frequent toxicities observed were grade 3 or 4 cytopenias involving neutropenia, thrombocytopenia and anaemia.
f’pazjenti pedjatriċi b’cml, l-aktar tossiċitajiet frekwenti kienu ċitopenji ta’ grad 3 jew 4 li jinvolvu newtropenji, tromboċitopenji u anemija.